Compare Incyte Corporation (INCY) vs PAGSEG Inc (PAGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs PAGSEG Inc — how do they compare? Incyte Corporation trades at $112.77 (market cap $22.85B), while PAGSEG Inc trades at $11.16 (market cap $2.94B). The key difference: Incyte Corporation is far larger — about 7.8× PAGSEG Inc's market cap, and PAGSEG Inc pays a 10.49% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and PAGSEG Inc for 26 Days on average.
| INCY | PAGS | |
|---|---|---|
Market Cap | $22.85B | $2.94B |
Volume | 1,927,029 | 4,242,708 |
Sector | Health | Industrials |
52-Week High | $129.93 | $12.00 |
52-Week Low | $83.80 | $8.44 |
Typical Hold Time | 33 Days | 26 Days |
Enterprise Value | $18.35B | $11.02B |
Dividend Yield | — | 10.49% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $113.61, up 0.15% on the day, with a mixed technical signal leaning bearish. The company reported strong 2025 results with revenue of $5.14B and net income of $1.29B, and recent earnings beats in Q1 and Q2 2026. Key developments include FDA approval for Atebrioz and a strategic focus on post-JAKAFI growth targeting $4B in non-JAKAFI sales by 2029.
The outlook is cautiously optimistic, supported by robust profitability and pipeline progress, but tempered by near-term earnings pressure and technical weakness. Risks include JAKAFI's patent expiration after 2029 and competitive threats. Analysts maintain a Buy consensus with a $132.43 price target, implying significant upside from current levels.
PAGS trades at $11.13, up 5.9% in the last 24 hours, with a bullish technical signal from moving averages. The stock shows strong fundamentals with a low P/E of 7.1 and robust profitability, including a 10.45% net income margin. Recent earnings beat expectations in Q2 2026, and the company maintains a solid dividend yield, supported by positive cash flow from operations of $7.56B in 2025.
The outlook for PAGS is positive, driven by undervaluation and earnings growth potential, but risks include macroeconomic pressures in Brazil and increased credit losses. Analyst consensus is strongly bullish with a $10.70 price target, though near-term volatility may persist due to mixed technical oscillators and competitive challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About PAGSEG Inc
PagSeguro Digital Ltd. is a leading provider of financial technology solutions in Brazil, primarily focused on e-commerce, face-to-face transactions, and financial services. The company's main offerings include PagBank, a digital banking platform, and PagSeguro, a suite of payment processing solutions that includes point-of-sale devices and online payment gateways. PAGS targets micro-merchants, small and medium-sized enterprises (SMEs), and consumers, aiming to democratize access to financial services in the country.
Read more on PAGS →
